PART I Overview We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The a...
Q2 FY2026 — expected 2026-09-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-06-23 | 2025-03-31 | 0001140361-25-023259 | EDGAR | 61K words |
| 2024-06-21 | 2024-03-31 | 0000950170-24-075875 | EDGAR | — |
| 2023-06-23 | 2023-03-31 | 0000950170-23-029498 | EDGAR | — |
| 2022-06-21 | 2022-03-31 | 0000950170-22-011842 | EDGAR | — |
| 2021-06-22 | 2021-03-31 | 0001171843-21-004462 | EDGAR | — |
| 2020-06-29 | 2020-03-31 | 0001171843-20-004613 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001140361-26-004924 | EDGAR | 23K words |
| 2025-11-13 | 2025-09-30 | 0001140361-25-041804 | EDGAR | — |
| 2025-08-12 | 2025-06-30 | 0001140361-25-030398 | EDGAR | — |
| 2025-02-13 | 2024-12-31 | 0001140361-25-004153 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001140361-24-046312 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094348 | EDGAR | — |
| 2024-02-12 | 2023-12-31 | 0000950170-24-013566 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062437 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041595 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0000950170-23-002695 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024666 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016632 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001140361-26-031671 | EDGAR | — |
| 2026-07-28 | 0001140361-26-029837 | EDGAR | — |
| 2026-02-12 | 0001140361-26-004927 | EDGAR | 4K words |
| 2026-01-12 | 0001140361-26-000995 | EDGAR | — |
| 2025-11-13 | 0001140361-25-041807 | EDGAR | — |
| 2025-10-23 | 0001140361-25-039020 | EDGAR | — |
| 2025-09-18 | 0001140361-25-035337 | EDGAR | — |
| 2025-09-12 | 0001140361-25-034845 | EDGAR | — |
| 2025-08-27 | 0001140361-25-032847 | EDGAR | — |
| 2025-08-12 | 0001140361-25-030400 | EDGAR | — |
364 total filings indexed. 336 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001444192 |
| Ticker | GRCE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gracetx.com |
| Listed | 2011-04-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GRCE (~200 tokens, structured JSON with cryptographic provenance)